Table 1.
Characteristics of patients at diagnosis.
| Case | Sex/Age | WBC(109/L) | BM blast(%) | Positive immunophenotype | Karyotype |
|---|---|---|---|---|---|
| ALL1 | F/70 | 13,620 | 92 | CD10, CD19, CD20, CD22, Cy-CD79a, CD34, HLA-DR | 46,XX,t(9;22)(q34;q11.2)[1]/45,idem,-7,add(19)(p13.3)[8]/ 46,XX[11] |
| ALL2 | F/50 | 3,570 | 99 | CD10, CD19, CD22, Cy-CD79a, CD33, CD34, HLA-DR | 46,XX,t(9;22)(q34;q11.2)[2]/ 46,idem,der(20)t(1;20)(q23;q13.1)[10]/46,XX[8] |
| ALL3 | F/35 | 172,530 | 97 | CD10, CD19, CD20, CD22, Cy-CD79a, CD33, CD34, HLA-DR | 46,XX,t(3;22;9)(p25;q11.2;q34)[20] |
| ALL4 | M/52 | 50,280 | 80 | CD10, CD19, CD20, CD22, Cy-CD79a, CD34, HLA-DR | 46,XY,der(9)del(9)(p13p22)t(9;22)(q34;q11.2),der(22)t(9;22)[12]/46,idem,del(11)(q11)[7]/46,XY[1] |
| ALL5 | F/52 | 9,260 | 90 | CD10, CD19, CD33, Cy-CD79a, CD34, HLA-DR | 45,XX,der(3;7)(q10;q10),t(9;22)(q34;q11.2)[15]/46,XX[5] |
| AML1 | F/57 | 89,170 | 75 | CD33, CD11c, CD14, CD64, CD117, Cy-MPO, CD10, CD19, CD56, CD34, HLA-DR | 46,XX,t(9;22)(q34;q11.2)[25]/46,XX[5] |
| AML2 | M/29 | 55,530 | 73 | CD33, CD11c, CD117, cy-MPO, CD19, CD34, HLA-DR | 46,XY,t(9;22)(q34;q11.2)[20] |
| AML3 | F/57 | 78,670 | 63 | CD13, CD33, CD11c, CD14, CD64, Cy-MPO, CD10, CD19, CD22, CD34, HLA-DR | 47,XX,+der(3;17)(q10;q10),t(9;22;14)(q34;q11.2;q32)[20] |
| MPAL1 | M/33 | 23,290 | 99 | CD10, CD19, CD79a, Cy-CD22, CD13, CD33, cy-MPO, CD7, CD34, HLA-DR | 45,XY,-7,t(9;22)(q34;q11.2) |
| MPAL2 | M/58 | 16,510 | 58 | CD10, CD19, CD79a, Cy-CD22, CD13, CD33, CD11c, CD64, Cy-MPO, CD7, CD34, HLA-DR | 46,XY,t(9;22)(q34;q11.2) |
| MPAL3 | F/56 | 6,820 | 83 | CD19, CD20, CD79a, Cy-CD22, CD13, CD33, Cy-MPO, CD34, HLA-DR | 49,XX,+X,+4,+8,t(9;22)(q34;q11.2),i(17)(q10)[5]/49,sl,add(4)(p16),-10,add(12)(p11.2),+mar[10]/49,sdl1,del(13)(q14)[2]/48,sdl2,-del(13q)[2]/50,sl,+8[2]/50,sl,der(3)t(3;?13)(q27;q13),+8[2]/46,XX[4] |
| MPAL4 | F/52 | 43,390 | 87 | CD10, CD19, CD22, Cy-CD79a, CD33, cy- MPO, CD7, CD34, HLA-DR | 45,XX,-7,t(9;22)(q34;q11.2)[18]/46,XX[2] |
WBC, while blood cell count; BM, bone marrow; ALL, acute lymphoblastic leukemia; MPAL, mixed-phenotype acute leukemia; AML, acute myeloid leukemia; cy-, cytoplasmic.